tiprankstipranks
Advertisement
Advertisement
Mereo BioPharma downgraded to Neutral from Overweight at JPMorgan
PremiumThe FlyMereo BioPharma downgraded to Neutral from Overweight at JPMorgan
2M ago
Mereo BioPharma downgraded to Neutral from Overweight at JPMorgan
Premium
The Fly
Mereo BioPharma downgraded to Neutral from Overweight at JPMorgan
2M ago
Balanced Risk-Reward Amid Clinical Uncertainty: Maintaining Hold on Mereo BioPharma
Premium
Ratings
Balanced Risk-Reward Amid Clinical Uncertainty: Maintaining Hold on Mereo BioPharma
2M ago
Mereo BioPharma Receives Nasdaq Minimum Bid Price Notice
PremiumCompany AnnouncementsMereo BioPharma Receives Nasdaq Minimum Bid Price Notice
3M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
4M ago
Mereo BioPharma Issues Corporate Update on Pipeline and Cash
Premium
Company Announcements
Mereo BioPharma Issues Corporate Update on Pipeline and Cash
4M ago
Mereo Biopharma: Depressed Valuation and Cost Controls Offset Setrusumab Trial Setback, Supporting Buy Rating on Upcoming Catalysts
PremiumRatingsMereo Biopharma: Depressed Valuation and Cost Controls Offset Setrusumab Trial Setback, Supporting Buy Rating on Upcoming Catalysts
5M ago
Mereo BioPharma downgraded to Hold from Buy at Jefferies
Premium
The Fly
Mereo BioPharma downgraded to Hold from Buy at Jefferies
5M ago
Ultragenyx price target lowered to $63 from $114 at Jefferies
Premium
The Fly
Ultragenyx price target lowered to $63 from $114 at Jefferies
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100